Details of Disease

General Information of Disease (ID: DISBZYU8)

Disease Name Prostate adenocarcinoma
Synonyms prad; adenocarcinoma of the prostate; adenocarcinoma of prostate; prostate adenocarcinoma; prostate gland adenocarcinoma
Definition A carcinoma that arises from glandular epithelial cells of the prostate gland
Disease Hierarchy
DISMJPLE: Prostate carcinoma
DIS3IHTY: Adenocarcinoma
DISBZYU8: Prostate adenocarcinoma
Disease Identifiers
MONDO ID
MONDO_0005082
UMLS CUI
C0007112
MedGen ID
764
SNOMED CT ID
399490008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 6 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Alendronate DMY2KX9 Approved Small molecular drug [1]
Docetaxel DMDI269 Approved Small molecular drug [2]
Dutasteride DMQ4TJK Approved Small molecular drug [3]
Ketoconazole DMPZI3Q Approved Small molecular drug [4]
Prednisone DM2HG4X Approved Small molecular drug [5]
Sunitinib DMCBJSR Approved Small molecular drug [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 33 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
AKT1 TTWTSCV Limited Altered Expression [7]
ERBB2 TTR5TV4 Limited Altered Expression [8]
MAP2K1 TTIDAPM Limited Genetic Variation [9]
PTEN TTXJ3W7 Limited Biomarker [10]
MYC TTNQ5ZP Disputed Altered Expression [11]
CLU TTRL76H moderate Therapeutic [12]
IGF1R TTQFBMY moderate Therapeutic [13]
PRKCQ TT1MS7X moderate Biomarker [14]
AGR2 TT9K86S Strong Altered Expression [15]
AR TTKPW01 Strong Biomarker [16]
BACH1 TT2ME4S Strong Altered Expression [17]
GRIA2 TTWM461 Strong Biomarker [18]
HOXB13 TTZ6I58 Strong Biomarker [19]
HPN TT25MVL Strong Altered Expression [20]
IDH1 TTV2A1R Strong Genetic Variation [9]
KDM3A TTKXS4A Strong Altered Expression [21]
KDR TTUTJGQ Strong Biomarker [22]
KLK14 TTDA81R Strong Altered Expression [23]
LIPE TTLUQ8E Strong Biomarker [24]
MSMB TTYH1ZK Strong Genetic Variation [25]
NPEPPS TT371QC Strong Genetic Variation [26]
OLFM4 TTK1CX7 Strong Posttranslational Modification [27]
OPRD1 TT27RFC Strong Biomarker [28]
PKN2 TTTHO0M Strong Biomarker [29]
PPP5C TTTW7FJ Strong Posttranslational Modification [30]
PPT1 TTSQC14 Strong Posttranslational Modification [30]
SLC18A2 TTNZRI3 Strong Altered Expression [31]
SLCO2B1 TTDL3UZ Strong Genetic Variation [32]
TMPRSS2 TT1GM2Z Strong Genetic Variation [33]
TNFRSF25 TTDV6BQ Strong Biomarker [34]
TRPV6 TTBK14N Strong Altered Expression [35]
XPO1 TTCJUR4 Strong Genetic Variation [9]
PRLR TTBPXMA Definitive Altered Expression [36]
------------------------------------------------------------------------------------
⏷ Show the Full List of 33 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC29A2 DTW78DQ Strong Genetic Variation [37]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP7B1 DE36TMY moderate Altered Expression [38]
DCXR DE3FEV8 Strong Biomarker [39]
PLPP1 DE6WXTH Strong Biomarker [40]
PSAT1 DEBS17P Strong Genetic Variation [26]
------------------------------------------------------------------------------------
This Disease Is Related to 72 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ERG OTOTX9VU Limited Biomarker [33]
KLK15 OT7BVG17 Limited Altered Expression [41]
LARP6 OTUQ9QS9 Limited Biomarker [42]
RAB8A OTPB54Y3 Limited Genetic Variation [42]
INSM1 OTG8RV8E moderate Altered Expression [43]
OTP OTS0JN6Y moderate Altered Expression [43]
SPOP OTP0107S moderate Biomarker [44]
ACY1 OT9WU7X3 Strong Altered Expression [45]
ALOX15B OTWQQ08W Strong Altered Expression [46]
ANP32A OTRHPFO2 Strong Altered Expression [47]
ANP32D OTAGQSQ6 Strong Altered Expression [47]
ARHGAP1 OT0H2ZBZ Strong Biomarker [48]
ARHGAP21 OT6XY8Y9 Strong Biomarker [48]
BMP3 OTCTI0UW Strong Altered Expression [49]
BPIFA2 OTLFSDZD Strong Genetic Variation [25]
CCDC115 OT04AZNZ Strong Altered Expression [50]
CIB1 OT4BVCRU Strong Altered Expression [51]
CNOT9 OT1NIIQD Strong Genetic Variation [9]
CRISP3 OTBSWMPL Strong Altered Expression [52]
DERL2 OTI3TUUZ Strong Genetic Variation [37]
DMTN OTDTKPBW Strong Biomarker [53]
DPT OTINRFC7 Strong Biomarker [34]
DVL3 OTPRROHJ Strong Biomarker [54]
EEF1A1 OT00THXS Strong Biomarker [55]
FRAT1 OT1PS84E Strong Biomarker [56]
FREM2 OTEK6BZR Strong Genetic Variation [57]
FRG1 OTEJ8HSD Strong Altered Expression [58]
FXYD3 OT9PPRHE Strong Biomarker [59]
GPSM1 OTA0SJBG Strong Altered Expression [60]
HADHB OT4Y1I62 Strong Altered Expression [61]
HES6 OTWO5SCF Strong Biomarker [21]
HPR OTXSC9UB Strong Biomarker [62]
KCTD11 OT64DFBU Strong Genetic Variation [63]
MED1 OTOO24C4 Strong Altered Expression [64]
MED12 OTQZ4D2X Strong Genetic Variation [9]
MYOD1 OTV2S79X Strong Posttranslational Modification [65]
ODF1 OTTSURLA Strong Altered Expression [66]
ODF4 OTP9AMYG Strong Biomarker [66]
ONECUT2 OTHUE5YY Strong Altered Expression [67]
PAF1 OTDDGUBQ Strong Biomarker [68]
PAQR3 OTTKJ9Y4 Strong Posttranslational Modification [69]
PEG10 OTWD2278 Strong Biomarker [70]
PHF21A OTU3FFG4 Strong Biomarker [71]
PIP OTH719AH Strong Altered Expression [72]
PLAG1 OTT9AJQY Strong Genetic Variation [26]
PLXNA1 OTN0BING Strong Altered Expression [73]
PMPCA OT5X1G9Q Strong Altered Expression [74]
PNPT1 OTBR2Q0F Strong Altered Expression [75]
PPP2R1A OTYA3GB4 Strong Genetic Variation [9]
PRM1 OT6HWA11 Strong Altered Expression [61]
PRM3 OT6574BF Strong Altered Expression [61]
PROS1 OTXQWNOI Strong Genetic Variation [26]
PSPH OTV1PVAX Strong Genetic Variation [25]
PSPN OT54LLZJ Strong Genetic Variation [25]
PYGO2 OTZHB2OI Strong Altered Expression [76]
RIDA OTW4098I Strong Genetic Variation [25]
RNASEH2B OT8KHYFY Strong Altered Expression [77]
RPL10 OTBHOZGC Strong Altered Expression [73]
SAT2 OT28QL7H Strong Altered Expression [78]
SERPINE2 OTYF5340 Strong Biomarker [79]
SH2B1 OTJZO2CI Strong Biomarker [80]
SH3GLB2 OTF7BB9S Strong Biomarker [81]
SIAH2 OTKED2XN Strong Altered Expression [21]
SIN3B OTFB59FK Strong Biomarker [82]
SPATA19 OT47CHQR Strong Biomarker [81]
SRRM4 OTALUISN Strong Biomarker [83]
STXBP3 OTTTYMAQ Strong Genetic Variation [25]
TDRD1 OT0CBCI3 Strong Biomarker [84]
TRAM1 OT3I0H8E Strong Biomarker [34]
TRIM16 OTLRXYOZ Strong Altered Expression [85]
FOXA2 OTJOCVOY Definitive Altered Expression [86]
KLF6 OTQY9S7F Definitive Biomarker [87]
------------------------------------------------------------------------------------
⏷ Show the Full List of 72 DOT(s)

References

1 Alendronate FDA Label
2 Docetaxel FDA Label
3 Dutasteride FDA Label
4 Ketoconazole FDA Label
5 Prednisone FDA Label
6 Sunitinib FDA Label
7 -Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice.Carcinogenesis. 2018 Feb 9;39(2):158-169. doi: 10.1093/carcin/bgx128.
8 Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.Am J Transl Res. 2019 Mar 15;11(3):1653-1667. eCollection 2019.
9 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
10 PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).Prostate. 2019 Aug;79(11):1267-1273. doi: 10.1002/pros.23831. Epub 2019 May 21.
11 MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer.J Pathol. 2018 Jan;244(1):11-24. doi: 10.1002/path.4980. Epub 2017 Nov 14.
12 Apocynin, an NADPH oxidase inhibitor, suppresses rat prostate carcinogenesis.Cancer Sci. 2013 Dec;104(12):1711-7. doi: 10.1111/cas.12292. Epub 2013 Oct 28.
13 Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7263-8. doi: 10.1073/pnas.93.14.7263.
14 Differential expression of protein kinase C isozyme messenger RNAs in dunning R-3327 rat prostatic tumors.Cell Growth Differ. 1994 Feb;5(2):143-9.
15 Differential expression of anterior gradient gene AGR2 in prostate cancer.BMC Cancer. 2010 Dec 13;10:680. doi: 10.1186/1471-2407-10-680.
16 DNA Damage Response in Prostate Cancer.Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):a030486. doi: 10.1101/cshperspect.a030486.
17 Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression.Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1495-1504. doi: 10.1080/21691401.2017.1374284. Epub 2017 Sep 11.
18 Anti-glutamate receptor 2 as a new potential diagnostic probe for prostatic adenocarcinoma: a pilot immunohistochemical study.Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):344-9. doi: 10.1097/PAI.0b013e31824013ba.
19 HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.Virchows Arch. 2017 Jul;471(1):133-136. doi: 10.1007/s00428-017-2134-y. Epub 2017 May 8.
20 The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.J Pathol. 2008 Jun;215(2):118-25. doi: 10.1002/path.2330.
21 The Siah2-HIF-FoxA2 axis in prostate cancer ?new markers and therapeutic opportunities.Oncotarget. 2010 Sep;1(5):379-85. doi: 10.18632/oncotarget.171.
22 Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55.Invest Radiol. 2010 Oct;45(10):573-8. doi: 10.1097/RLI.0b013e3181ee8b83.
23 High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.Tumour Biol. 2008;29(1):1-8. doi: 10.1159/000132565. Epub 2008 May 23.
24 Differential Modulation of Transcription Factors and Cytoskeletal Proteins in Prostate Carcinoma Cells by a Bacterial Lactone.Biomed Res Int. 2018 May 9;2018:6430504. doi: 10.1155/2018/6430504. eCollection 2018.
25 A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies.Mol Ther. 2005 Mar;11(3):348-62. doi: 10.1016/j.ymthe.2004.12.005.
26 Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.Clin Nucl Med. 2019 Apr;44(4):e313-e314. doi: 10.1097/RLU.0000000000002489.
27 Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.Int J Cancer. 2020 Mar 1;146(5):1346-1358. doi: 10.1002/ijc.32535. Epub 2019 Jul 9.
28 Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization.Virchows Arch. 1998 Oct;433(4):297-304. doi: 10.1007/s004280050252.
29 Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer.Oncotarget. 2015 Sep 22;6(28):26437-56. doi: 10.18632/oncotarget.4664.
30 The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.PLoS One. 2011 Feb 17;6(2):e14700. doi: 10.1371/journal.pone.0014700.
31 Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.Clin Cancer Res. 2009 Feb 15;15(4):1400-10. doi: 10.1158/1078-0432.CCR-08-2268.
32 CTHRC1 and PD?/PDL1 expression predicts tumor recurrence in prostate cancer.Mol Med Rep. 2019 Nov;20(5):4244-4252. doi: 10.3892/mmr.2019.10690. Epub 2019 Sep 19.
33 Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.Int J Cancer. 2020 Apr 1;146(7):2036-2046. doi: 10.1002/ijc.32792. Epub 2019 Nov 29.
34 Systemic alkalinisation delays prostate cancer cell progression in TRAMP mice.J Enzyme Inhib Med Chem. 2017 Dec;32(1):363-368. doi: 10.1080/14756366.2016.1252760.
35 TRPV6 alleles do not influence prostate cancer progression.BMC Cancer. 2009 Oct 26;9:380. doi: 10.1186/1471-2407-9-380.
36 Fibroblast growth factor, estrogen, and prolactin receptor features in different grades of prostatic adenocarcinoma in elderly men.Microsc Res Tech. 2013 Mar;76(3):321-30. doi: 10.1002/jemt.22170. Epub 2013 Jan 30.
37 Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate.Cancer Genet Cytogenet. 1988 Oct 1;35(1):103-8. doi: 10.1016/0165-4608(88)90128-8.
38 Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.Prostate. 2007 Sep 15;67(13):1439-46. doi: 10.1002/pros.20630.
39 Dicarbonyl/L-xylulose reductase: a potential biomarker identified by laser-capture microdissection-micro serial analysis of gene expression of human prostate adenocarcinoma.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2615-22. doi: 10.1158/1055-9965.EPI-07-0684.
40 Identification of the phosphatidic acid phosphatase type 2a isozyme as an androgen-regulated gene in the human prostatic adenocarcinoma cell line LNCaP.J Biol Chem. 1998 Feb 20;273(8):4660-5. doi: 10.1074/jbc.273.8.4660.
41 KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.Int J Cancer. 2010 Nov 15;127(10):2386-94. doi: 10.1002/ijc.25435.
42 Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.J Nat Prod. 2017 Jul 28;80(7):1981-1991. doi: 10.1021/acs.jnatprod.6b01129. Epub 2017 Jun 15.
43 Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.Endocr Pathol. 2019 Mar;30(1):35-42. doi: 10.1007/s12022-018-9559-y.
44 SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.Oncogene. 2017 Aug 17;36(33):4767-4777. doi: 10.1038/onc.2017.80. Epub 2017 Apr 17.
45 A human gene encoding diazepam-binding inhibitor/acy1-CoA-binding protein: transcription and hormonal regulation in the androgen-sensitive human prostatic adenocarcinoma cell line LNCaP.DNA Cell Biol. 1996 Mar;15(3):197-208. doi: 10.1089/dna.1996.15.197.
46 Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma.Neoplasia. 2001 Jul-Aug;3(4):287-303. doi: 10.1038/sj.neo.7900166.
47 Tumor suppression and potentiation by manipulation of pp32 expression.Oncogene. 2001 Apr 19;20(17):2153-60. doi: 10.1038/sj.onc.1204294.
48 ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Biochim Biophys Acta. 2013 Feb;1832(2):365-74. doi: 10.1016/j.bbadis.2012.11.010. Epub 2012 Nov 28.
49 Sequence and expression of bone morphogenetic protein 3 mRNA in prolonged cultures of fetal rat calvarial osteoblasts and in rat prostate adenocarcinoma PA III cells.DNA Cell Biol. 1995 Mar;14(3):235-9. doi: 10.1089/dna.1995.14.235.
50 Modifier locus mapping of a transgenic F2 mouse population identifies CCDC115 as a novel aggressive prostate cancer modifier gene in humans.BMC Genomics. 2018 Jun 11;19(1):450. doi: 10.1186/s12864-018-4827-2.
51 Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.Pathol Oncol Res. 2008 Sep;14(3):307-11. doi: 10.1007/s12253-008-9042-z. Epub 2008 Apr 16.
52 Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer.Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1419-26.
53 Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression.Cancer Genet Cytogenet. 1999 Nov;115(1):65-9. doi: 10.1016/s0165-4608(99)00081-3.
54 Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.BJU Int. 2017 Sep;120(3):343-350. doi: 10.1111/bju.13783. Epub 2017 Feb 10.
55 Prostate-tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection.Cancer Invest. 2008 Oct;26(8):800-8. doi: 10.1080/07357900701874633.
56 Frequently rearranged in advanced Tcell lymphomas? demonstrates oncogenic properties in prostate cancer.Mol Med Rep. 2016 Oct;14(4):3551-8. doi: 10.3892/mmr.2016.5704. Epub 2016 Sep 5.
57 Integrative analysis of cancer driver genes in prostate adenocarcinoma.Mol Med Rep. 2019 Apr;19(4):2707-2715. doi: 10.3892/mmr.2019.9902. Epub 2019 Jan 28.
58 Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.BMC Cancer. 2019 Apr 11;19(1):346. doi: 10.1186/s12885-019-5509-4.
59 Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer.Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4473-E4482. doi: 10.1073/pnas.1802354115. Epub 2018 Apr 23.
60 Activator of G protein signaling 3 modulates prostate tumor development and progression.Carcinogenesis. 2019 Dec 31;40(12):1504-1513. doi: 10.1093/carcin/bgz076.
61 Regulated expression of the TP isoform of the human T prostanoid receptor by the tumour suppressors FOXP1 and NKX3.1: Implications for the role of thromboxane in prostate cancer.Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3153-3169. doi: 10.1016/j.bbadis.2017.09.005. Epub 2017 Sep 8.
62 In vitro anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma.Anticancer Res. 1995 Jul-Aug;15(4):1429-34.
63 KCTD11 tumor suppressor gene expression is reduced in prostate adenocarcinoma.Biomed Res Int. 2014;2014:380398. doi: 10.1155/2014/380398. Epub 2014 Jun 19.
64 ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.Mol Cancer Res. 2013 Jul;11(7):736-47. doi: 10.1158/1541-7786.MCR-12-0618. Epub 2013 Mar 28.
65 Role of glutathione-S-transferase P1 hypermethylation in molecular detection of prostate cancer.Genet Test Mol Biomarkers. 2011 Oct;15(10):667-70. doi: 10.1089/gtmb.2010.0262. Epub 2011 Jun 1.
66 Expression of splice variants of cancer-testis genes ODF3 and ODF4 in the testis of a prostate cancer patient.Genet Mol Res. 2012 Oct 4;11(4):3642-8. doi: 10.4238/2012.October.4.11.
67 ONECUT2 is a driver of neuroendocrine prostate cancer.Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.
68 New platinum (II) and palladium (II) complexes of coumarin-thiazole Schiff base with a fluorescent chemosensor properties: Synthesis, spectroscopic characterization, X-ray structure determination, in vitro anticancer activity on various human carcinoma cell lines and computational studies.J Photochem Photobiol B. 2018 Jan;178:428-439. doi: 10.1016/j.jphotobiol.2017.11.030. Epub 2017 Nov 22.
69 Aberrant promoter methylation of the PAQR3 gene is associated with prostate cancer.Pathol Res Pract. 2018 Jan;214(1):126-129. doi: 10.1016/j.prp.2017.10.010. Epub 2017 Oct 10.
70 A bioinformatics-to-clinic sequential approach to analysis of prostate cancer biomarkers using TCGA datasets and clinical samples: a new method for precision oncology?.Oncotarget. 2017 Aug 24;8(59):99601-99611. doi: 10.18632/oncotarget.20448. eCollection 2017 Nov 21.
71 RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.Eur Urol. 2019 Aug;76(2):157-166. doi: 10.1016/j.eururo.2019.03.011. Epub 2019 Mar 23.
72 Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate.Cancer Sci. 2004 Jun;95(6):491-5. doi: 10.1111/j.1349-7006.2004.tb03238.x.
73 Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues.Mol Pathol. 2001 Aug;54(4):275-80. doi: 10.1136/mp.54.4.275.
74 Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids.Oncotarget. 2017 Apr 19;8(31):51264-51276. doi: 10.18632/oncotarget.17230. eCollection 2017 Aug 1.
75 Analysis of global changes in gene expression induced by human polynucleotide phosphorylase (hPNPase(old-35)).J Cell Physiol. 2014 Dec;229(12):1952-62. doi: 10.1002/jcp.24645.
76 PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.J Clin Pathol. 2018 May;71(5):402-411. doi: 10.1136/jclinpath-2017-204718. Epub 2017 Sep 18.
77 Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.Oncogene. 2019 Apr;38(14):2451-2463. doi: 10.1038/s41388-018-0606-4. Epub 2018 Dec 7.
78 Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm.Virchows Arch. 2009 Jan;454(1):17-23. doi: 10.1007/s00428-008-0706-6. Epub 2008 Dec 2.
79 Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.J Clin Invest. 2012 Nov;122(11):4025-36. doi: 10.1172/JCI59348. Epub 2012 Oct 8.
80 Prostate-specific membrane antigen.Prostate. 1997 Jul 1;32(2):140-8. doi: 10.1002/(sici)1097-0045(19970701)32:2<140::aid-pros9>3.0.co;2-q.
81 SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3509-14. doi: 10.1073/pnas.0712269105. Epub 2008 Feb 26.
82 Chromatin-Associated Protein SIN3B Prevents Prostate Cancer Progression by Inducing Senescence.Cancer Res. 2017 Oct 1;77(19):5339-5348. doi: 10.1158/0008-5472.CAN-16-3410. Epub 2017 Aug 14.
83 SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.Eur Urol. 2017 Jan;71(1):68-78. doi: 10.1016/j.eururo.2016.04.028. Epub 2016 May 11.
84 Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.Pathol Res Pract. 2018 Nov;214(11):1811-1817. doi: 10.1016/j.prp.2018.08.029. Epub 2018 Aug 29.
85 TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway.Int J Mol Med. 2016 Dec;38(6):1734-1742. doi: 10.3892/ijmm.2016.2774. Epub 2016 Oct 17.
86 FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate.Mod Pathol. 2017 Sep;30(9):1262-1272. doi: 10.1038/modpathol.2017.44. Epub 2017 Jun 16.
87 Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11.Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2551-6. doi: 10.1073/pnas.93.6.2551.